FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB Share Price

DE000SD5K2L6

Delayed Deutsche Boerse AG 09:08:27 03/06/2024 pm IST
5.3 ^EUR	-16.14%

1 month	+58.00%
3 months	+189.91%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	07:44pm	BU
Bristol Myers: presents advances in lung cancer	06:28pm	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	05:39pm	BU
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE

More news

Quotes 5-day view

Date	Price	Change
03/24/03	5.3	-16.14%
31/24/31	6.32	-9.84%
30/24/30	7.01	+0.86%
29/24/29	6.95	+1.46%
28/24/28	6.85	+19.34%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 09:08 pm IST

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SD5K2L
ISIN	DE000SD5K2L6
Date issued	21/04/2021
Strike	65.6 $
Maturity	Unlimited
Parity	1 : 1
Emission price	10 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	23.73 €
Lowest since issue	0.3 €
Spread	0.05 €
Spread %	0.91%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus